SLC5A2 and heart failure: Furthermore, treatment with the SGLT2 inhibitor empagliflozin was associated with reduced risk of CV death, hospitalization for heart failure, CV death or hospitalization for heart failure, and 3P-MACE versus placebo regardless of the level of CV risk factor control at baseline.